As of 2026-03-28, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -3.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 433.74 mil USD. VNDA's TTM EBITDA according to its financial statements is -123.53 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 14.9x | 14.0x |
| Forward P/E multiples | 15.1x - 20.1x | 17.8x |
| Fair Price | (24.17) - (23.84) | (25.47) |
| Upside | -449.8% - -445.0% | -468.5% |
| Date | EV/EBITDA |
| 2026-03-24 | -3.46 |
| 2026-03-23 | -3.57 |
| 2026-03-20 | -3.64 |
| 2026-03-19 | -4.51 |
| 2026-03-18 | -4.50 |
| 2026-03-17 | -4.52 |
| 2026-03-16 | -4.65 |
| 2026-03-13 | -4.65 |
| 2026-03-12 | -4.94 |
| 2026-03-11 | -4.94 |
| 2026-03-10 | -5.10 |
| 2026-03-09 | -4.57 |
| 2026-03-06 | -4.10 |
| 2026-03-05 | -4.11 |
| 2026-03-04 | -4.28 |
| 2026-03-03 | -4.07 |
| 2026-03-02 | -4.27 |
| 2026-02-27 | -4.71 |
| 2026-02-26 | -4.52 |
| 2026-02-25 | -4.33 |
| 2026-02-24 | -4.27 |
| 2026-02-23 | -4.25 |
| 2026-02-20 | -2.82 |
| 2026-02-19 | -3.03 |
| 2026-02-18 | -2.98 |
| 2026-02-17 | -3.09 |
| 2026-02-13 | -3.02 |
| 2026-02-12 | -3.04 |
| 2026-02-11 | -3.82 |
| 2026-02-10 | -3.82 |
| 2026-02-09 | -3.87 |
| 2026-02-06 | -3.91 |
| 2026-02-05 | -3.70 |
| 2026-02-04 | -3.92 |
| 2026-02-03 | -4.19 |
| 2026-02-02 | -4.01 |
| 2026-01-30 | -3.89 |
| 2026-01-29 | -4.03 |
| 2026-01-28 | -3.98 |
| 2026-01-27 | -4.18 |
| 2026-01-26 | -4.03 |
| 2026-01-23 | -4.17 |
| 2026-01-22 | -4.22 |
| 2026-01-21 | -4.12 |
| 2026-01-20 | -3.99 |
| 2026-01-16 | -3.85 |
| 2026-01-15 | -3.83 |
| 2026-01-14 | -3.98 |
| 2026-01-13 | -3.83 |
| 2026-01-12 | -3.81 |